Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism

Tauheed Ishrat, Anna Kozak, Ahmed Alhusban, Bindu Pillai, Maribeth H Johnson, Azza B. El-Remessy, Adviye Ergul, Susan C. Fagan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP activity while providing neurovascular protection. We aimed to determine the contribution of MMP and nitrative stress to the effects of angiotensin blockade in experimental stroke. Methods. Wistar rats (n = 9-14/group; a total of 99) were treated in a factorial design with candesartan 1 mg/kg IV, alone or in combination with either a peroxynitrite decomposition catalyst, FeTPPs, 30 mg/kg IP or GM6001 50 mg/kg IP (MMP inhibitor). Neurological deficit, infarct, size and hemorrhagic transformation (HT) were measured after 3 h of middle cerebral artery occlusion (MCAO) and 21 h of reperfusion. MMP activity and nitrotyrosine expression were also measured. Results. Candesartan reduced infarct size and HT when administered alone (P = 0.0011) and in combination with FeTPPs (P = 0.0016). GM6001 did not significantly affect HT when administered alone, but the combination with candesartan caused increased HT (P < 0.0001) and worsened neurologic score (P = 0.028). Conclusions. Acute administration of candesartan reduces injury after stroke despite increasing MMP activity, likely by an antioxidant mechanism.

Original languageEnglish (US)
Article number560491
JournalStroke Research and Treatment
Volume2014
DOIs
StatePublished - Jan 1 2014

Fingerprint

Angiotensins
Matrix Metalloproteinases
Stroke
Angiotensin II Type 1 Receptor Blockers
Peroxynitrous Acid
Matrix Metalloproteinase Inhibitors
Middle Cerebral Artery Infarction
Nervous System
Reperfusion
Blood Vessels
Wistar Rats
Oxidative Stress
Antioxidants
candesartan
Wounds and Injuries
N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism. / Ishrat, Tauheed; Kozak, Anna; Alhusban, Ahmed; Pillai, Bindu; Johnson, Maribeth H; El-Remessy, Azza B.; Ergul, Adviye; Fagan, Susan C.

In: Stroke Research and Treatment, Vol. 2014, 560491, 01.01.2014.

Research output: Contribution to journalArticle

Ishrat, Tauheed ; Kozak, Anna ; Alhusban, Ahmed ; Pillai, Bindu ; Johnson, Maribeth H ; El-Remessy, Azza B. ; Ergul, Adviye ; Fagan, Susan C. / Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism. In: Stroke Research and Treatment. 2014 ; Vol. 2014.
@article{fce7858049c34ecea250a8362e5b9161,
title = "Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism",
abstract = "Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP activity while providing neurovascular protection. We aimed to determine the contribution of MMP and nitrative stress to the effects of angiotensin blockade in experimental stroke. Methods. Wistar rats (n = 9-14/group; a total of 99) were treated in a factorial design with candesartan 1 mg/kg IV, alone or in combination with either a peroxynitrite decomposition catalyst, FeTPPs, 30 mg/kg IP or GM6001 50 mg/kg IP (MMP inhibitor). Neurological deficit, infarct, size and hemorrhagic transformation (HT) were measured after 3 h of middle cerebral artery occlusion (MCAO) and 21 h of reperfusion. MMP activity and nitrotyrosine expression were also measured. Results. Candesartan reduced infarct size and HT when administered alone (P = 0.0011) and in combination with FeTPPs (P = 0.0016). GM6001 did not significantly affect HT when administered alone, but the combination with candesartan caused increased HT (P < 0.0001) and worsened neurologic score (P = 0.028). Conclusions. Acute administration of candesartan reduces injury after stroke despite increasing MMP activity, likely by an antioxidant mechanism.",
author = "Tauheed Ishrat and Anna Kozak and Ahmed Alhusban and Bindu Pillai and Johnson, {Maribeth H} and El-Remessy, {Azza B.} and Adviye Ergul and Fagan, {Susan C.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1155/2014/560491",
language = "English (US)",
volume = "2014",
journal = "Stroke Research and Treatment",
issn = "2090-8105",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism

AU - Ishrat, Tauheed

AU - Kozak, Anna

AU - Alhusban, Ahmed

AU - Pillai, Bindu

AU - Johnson, Maribeth H

AU - El-Remessy, Azza B.

AU - Ergul, Adviye

AU - Fagan, Susan C.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP activity while providing neurovascular protection. We aimed to determine the contribution of MMP and nitrative stress to the effects of angiotensin blockade in experimental stroke. Methods. Wistar rats (n = 9-14/group; a total of 99) were treated in a factorial design with candesartan 1 mg/kg IV, alone or in combination with either a peroxynitrite decomposition catalyst, FeTPPs, 30 mg/kg IP or GM6001 50 mg/kg IP (MMP inhibitor). Neurological deficit, infarct, size and hemorrhagic transformation (HT) were measured after 3 h of middle cerebral artery occlusion (MCAO) and 21 h of reperfusion. MMP activity and nitrotyrosine expression were also measured. Results. Candesartan reduced infarct size and HT when administered alone (P = 0.0011) and in combination with FeTPPs (P = 0.0016). GM6001 did not significantly affect HT when administered alone, but the combination with candesartan caused increased HT (P < 0.0001) and worsened neurologic score (P = 0.028). Conclusions. Acute administration of candesartan reduces injury after stroke despite increasing MMP activity, likely by an antioxidant mechanism.

AB - Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP activity while providing neurovascular protection. We aimed to determine the contribution of MMP and nitrative stress to the effects of angiotensin blockade in experimental stroke. Methods. Wistar rats (n = 9-14/group; a total of 99) were treated in a factorial design with candesartan 1 mg/kg IV, alone or in combination with either a peroxynitrite decomposition catalyst, FeTPPs, 30 mg/kg IP or GM6001 50 mg/kg IP (MMP inhibitor). Neurological deficit, infarct, size and hemorrhagic transformation (HT) were measured after 3 h of middle cerebral artery occlusion (MCAO) and 21 h of reperfusion. MMP activity and nitrotyrosine expression were also measured. Results. Candesartan reduced infarct size and HT when administered alone (P = 0.0011) and in combination with FeTPPs (P = 0.0016). GM6001 did not significantly affect HT when administered alone, but the combination with candesartan caused increased HT (P < 0.0001) and worsened neurologic score (P = 0.028). Conclusions. Acute administration of candesartan reduces injury after stroke despite increasing MMP activity, likely by an antioxidant mechanism.

UR - http://www.scopus.com/inward/record.url?scp=84934982931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934982931&partnerID=8YFLogxK

U2 - 10.1155/2014/560491

DO - 10.1155/2014/560491

M3 - Article

AN - SCOPUS:84934982931

VL - 2014

JO - Stroke Research and Treatment

JF - Stroke Research and Treatment

SN - 2090-8105

M1 - 560491

ER -